«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

30卷

期数:

2024年06期

页码:

485-490

栏目:

肿瘤疾病专题

出版日期:

2024-11-20

文章信息/Info

Title:

Expression and clinical significance of LncRNA FAM83H-AS1 and miR-136 in epithelial ovarian cancer

文章编号:

1006-8147(2024)06-0485-06

作者:

王军¹; 张占薪¹; 王佳佳²; 郭伟平¹; 苏倩倩¹; 张博慧¹; 吴启文¹; 宋晓霞¹

（1.河南中医药大学第五临床医学院（郑州人民医院）妇科；2.河南中医药大学第五临床医学院（郑州人民医院）病理科，郑州 450000）

Author(s):

WANG Jun¹; ZHANG Zhanxin¹; WANG Jiajia²; GUO Weiping¹; SU Qianqian¹; ZHANG Bohui¹; WU Qiwen¹; SONG Xiaoxia¹

（1.Department of Gynecology，The Fifth Clinical Medical College of Henan University of Chinese Medicine（Zhengzhou People′s Hospital），Zhengzhou 450000，China；2.Department of Pathology，The Fifth Clinical Medical College of Henan University of Chinese Medicine（Zhengzhou People′s Hospital），Zhengzhou 450000，China）

关键词:

上皮性卵巢癌; 长链非编码RNA FAM83H-AS1; 微小RNA-136; 生存期

Keywords:

epithelial ovarian cancer; long non-coding RNA FAM83H-AS1; microRNA-136; duration of survival

分类号:

R71

DOI:

10.20135/j.issn.1006-8147.2024.06.0485

文献标志码:

A

摘要:

目的：探讨长链非编码RNA（LncRNA） FAM83H-AS1和miR-136在上皮性卵巢癌（EOC）组织中的表达及其临床意义。方法：收集2019年6月—2021年6月在郑州人民医院妇科手术治疗的68例EOC 患者的EOC组织（EOC组）及68例非肿瘤卵巢组织（对照组），检测两组FAM83H-AS1及miR-136的表达水平并分析二者的相关性；根据FAM83H-AS1及miR-136表达的中位值将EOC患者分为FAM83H-AS1低表达组、高表达组和miR-136低表达组、高表达组，并分析不同分组EOC患者临床病理特征、无进展生存期（PFS）和总生存期（OS）的差异；将miR-136 mimic及mimic-NC分别与FAM83H-AS1-wt、FAM83H-AS1-mut共转染至293T细胞中，然后采用双荧光素酶报告基因实验证实FAM83H-AS1与miR-136的靶向关系。结果：与对照组相比，EOC组FAM83H-AS1表达水平明显升高，miR-136表达水平明显降低（t=21.636、22.050，均P<0.05），且二者呈负相关（r=-0.283，P=0.019）。不同FAM83H-AS1、miR-136分组间FIGO分期（χ2=13.247、4.769，均P<0.05）及淋巴结转移均有明显差异（χ2=11.698、4.140，均P<0.05）。FAM83H-AS1高表达组患者的OS和PFS低于低表达组（均P<0.05），而miR-136高表达组患者的OS和PFS高于低表达组（均P<0.05）；FAM83H-AS1是EOC患者PFS的独立影响因素之一（HR=2.438，95%CI：1.055~5.638，P<0.05），而miR-136是OS的独立影响因素之一（HR=0.401，95%CI：0.162~0.991，P<0.05）。双荧光素酶报告基因实验证实FAM83H-AS1与miR-136存在靶向关系。结论：FAM83H-AS1与miR-136在EOC中异常表达，二者均可作为EOC患者的潜在预后评估指标。

Abstract:

Objective：To investigate the expression and clinical significance of lncRNA FAM83H-AS1 and miR-136 in epithelial ovarian cancer （EOC） tissues. Methods：A total of 68 cases of EOC tissue （EOC group） and 68 cases of non-tumor ovarian tissue （control group） were collected in the Department of Gynecology，Zhengzhou People′s Hospital from June 2019 to June 2021，the expression levels of FAM83H-AS1 and miR-136 in two groups were detected and the correlation between two groups was analyzed. According to the median value of FAM83H-AS1 and miR-136 expression，patients with EOC were divided into FAM83H-AS1 low expression group，high expression group，and miR-136 low expression group and high expression group. The clinicopathological characteristics，progression-free survival （PFS） and overall survival （OS） of EOC patients in different groups were analyzed. MiR-136 mimic and mimic-NC were co-transfected into 293T cells with FAM83H-AS1-wt and FAM83H-AS1-mut，respectively，and then dual luciferase reporter gene assay was used to verify the targeting relationship between FAM83H-AS1 and miR-136. Results：Compared with the control group，the expression level of FAM83H-AS1 in the EOC group was significantly increased，and the expression level of miR-136 was significantly decreased （t=21.636，22.050，all P<0.05），their expression was reversely correlated （t=-0.283，P=0.019）. There were significant differences in FIGO stage （χ2=13.247，4.769，all P<0.05） and lymph node metastasis （χ2=11.698，4.140，all P<0.05） among FAM83H-AS1 and miR-136 groups. The OS and PFS of the high FAM83H-AS1 group were lower than those of the low FAM83H-AS1 group （P<0.05），while the OS and PFS of the high miR-136 group were higher than those of the low miR-136 group （P<0.05）. FAM83H-AS1 was an independent influencing factor for PFS in EOC patients （HR= 2.438，95%CI：1.055-5.638，P<0.05），while miR-136 was an independent influencing factor for OS in EOC patients （HR=0.401，95%CI：0.162-0.991，P<0.05）. The dual luciferase reporter gene assay confirmed the targeting relationship between FAM83H-AS1 and miR-136. Conclusion： FAM83H-AS1 and miR-136 are abnormally expressed in EOC，and both can be used as potential indicators for evaluating the prognosis of EOC patients.

参考文献/References:

[1] TORRE L A，TRABERT B，DESANTIS C E，et al. Ovarian cancer statistics，2018[J]. CA Cancer J Clin，2018，68（4）：284-296.
[2] PRONINA I V，UROSHLEV L A，MOSKOVTSEV A A，et al. Dysregulation of lncRNA-miRNA-mRNA interactome as a marker of metastatic process in ovarian cancer[J]. Biomedicines，2022，10（4）：824.
[3] ZHOU Y，ZHENG X，XU B，et al. The identification and analysis of mRNA-lncRNA-miRNA cliques from the integrative network of ovarian cancer[J]. Front Genet，2019，10：751.
[4] YANG Q，WANG J，ZHONG P，et al. The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients： a meta-analysis[J]. Cancer Cell Int，2020，20：72.
[5] CHU Y，HU X，WANG G，et al. Downregulation of miR-136 promotes the progression of osteosarcoma and is associated with the prognosis of patients with osteosarcoma[J]. Oncol Lett，2019，17（6）：5210-5218.
[6] 武利伟，龙美跃，胡耀文，等. LncRNA FAM83H-AS1调控miR-136-5p/HOXC10轴对胶质瘤细胞增殖和凋亡的影响[J]. 临床神经外科杂志，2022，19（6）：654-660.
[7] HAN C，FU Y，ZENG N，et al. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis[J]. Aging （Albany NY），2020，12（4）：3594-3616.
[8] 鞠策，高景春，张朋新，等. PD-1和PD-L1在卵巢上皮性癌组织中的表达及其意义[J]. 中华妇产科杂志，2020，55（8）：529-534.
[9] YANG L，CUI J，WANG Y，et al. FAM83H-AS1 is upregulated and predicts poor prognosis in colon cancer[J]. Biomed Pharmacother，2019，118：109342.
[10] YANG F，LV SX，LV L，et al. Identification of lncRNA FAM83H-AS1 as a novel prognostic marker in luminal subtype breast cancer[J]. Onco Targets Ther，2016，9：7039-7045.
[11] YUAN X，HUANG Y，GUO M，et al. Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer[J]. J Ovarian Res，2021，14（1）：6.
[12] GONG Y B，ZOU Y F. Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer[J]. Eur Rev Med Pharmacol Sci，2019，23（11）：4656-4662.
[13] DOU Q，XU Y，ZHU Y，et al. LncRNA FAM83H-AS1 contributes to the radioresistance，proliferation，and metastasis in ovarian cancer through stabilizing HuR protein[J]. Eur J Pharmacol，2019，852：134-141.
[14] 陈秀敏，刘族志，林建能. 血浆miR-136-5p表达水平对口腔鳞状细胞癌患者预后预测的价值[J]. 中国口腔颌面外科杂志，2020，18（6）：526-530.
[15] GUO T，PAN G. MicroRNA-136 functions as a tumor suppressor in osteosarcoma via regulating metadherin[J]. Cancer Biomark，2018， 22（1）：79-87.
[16] ZHAO H，LIU S，WANG G，et al. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer[J]. Oncol Rep，2015，33（2）：591-598.
[17] JEONG J Y，KANG H，KIM T H，et al. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3[J]. Cancer Lett，2017，386：168-178.
[18] 时彩艳，刘峰，卢宏全，等. FAM83H-AS1靶向miR-4684-5p对胰腺癌细胞放射敏感性的影响[J]. 局解手术学杂志，2022，31（5）：396-402.
[19] JIANG X，CHEN D. LncRNA FAM83H-AS1 maintains intervertebral disc tissue homeostasis and attenuates inflammation-related pain via promoting nucleus pulposus cell growth through miR-22-3p inhibition[J]. Ann Transl Med，2020，8（22）：1518.

相似文献/References:

[1]黄小娟,王俊艳,齐文慧,等.Axl及其配体Gas6在I型和 II型上皮性卵巢癌中的表达和意义[J].天津医科大学学报,2014,20(05):342.
　HUANG Xiao-juan,WANG Jun-yan,QI Wen-hui,et al.Expression of Axl and its ligand in type I and II epithelial ovarian carcinoma and its clinical significance[J].Journal of Tianjin Medical University,2014,20(06):342.
[2]张宁,金嘉琪,张少璐,等.ITSN1基因与卵巢癌化疗敏感性和预后的关系[J].天津医科大学学报,2023,29(04):354.
　ZHANG Ning,JIN Jia-qi,ZHANG Shao-lu,et al.Association of ITSN1 gene with chemosensitivity and prognosis in ovarian cancer[J].Journal of Tianjin Medical University,2023,29(06):354.

备注/Memo

备注/Memo:

基金项目 2022年度河南省医学科技攻关计划联合共建项目（LHGJ20220794）
作者简介 王军（1985-），男，主治医师，学士，研究方向：妇科肿瘤学；
通信作者：宋晓霞，E-mail：ssxxx19@163.com。

常用功能

更新日期/Last Update: 2024-11-25